Following Thai adults with transthyretin amyloid heart disease over time
Tracks how transthyretin amyloid heart disease appears and changes in adults in Thailand.
Plain-language title generated from the registry record
Registry title: Thailand ATTR-CM Registry
Key facts
- Where
- Bangkok, Chiang Mai, Khon Kaen, Pathum Thani, and Songkhla, ThailandSee the 8 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT06338696, who can take part
Where in Thailand
- Faculty of Medicine at Chulalongkorn UniversityBangkok, ThailandNot yet recruiting
- Faculty of Medicine Siriraj Hospital, Mahidol UniversityBangkok, ThailandNot yet recruiting
- Faculty of Medicine, Ramathibodi Hospital, Mahidol UniversityBangkok, ThailandNot yet recruiting
- Phramongkutklao HospitalBangkok, ThailandNot yet recruiting
- Faculty of Medicine, Chiang Mai UniversityChiang Mai, ThailandNot yet recruiting
- Queen Sirikit Heart Center of The NortheastKhon Kaen, ThailandNot yet recruiting
- Faculty of Medicine, Thammasat UniversityPathum Thani, ThailandNot yet recruiting
- Prince of Songkla UniversitySongkhla, ThailandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mahidol University
- Trial code
- NCT06338696
- Record updated
- 8 May 2025
- Original description
The investigators of this registry aim to study the natural history, clinical presentation, characteristics, and imaging findings of patients diagnosed with ATTR amyloidosis in Thailand longitudinally. This will enable the investigators to study this disease in depth. With a better understanding, the investigators can aim to develop early screening programs for at-risk patients, raising awareness among non-cardiologists. As amyloid-specific therapies have now become available in Thailand, the findings of this registry can be helpful for epidemiological studies in Thailand.Read full original descriptionShow less
Thailand Transthyretin Amyloid Cardiomyopathy Registry
The investigators of this registry aim to study the natural history, clinical presentation, characteristics, and imaging findings of patients diagnosed with ATTR amyloidosis in Thailand longitudinally. This will enable the investigators to study this disease in depth. With a better understanding, the investigators can aim to develop early screening programs for at-risk patients, raising awareness among non-cardiologists. As amyloid-specific therapies have now become available in Thailand, the findings of this registry can be helpful for epidemiological studies in Thailand.
Inclusion: Age > 18 years; All patients diagnosed with ATTR-CM (Transthyretin cardiomyopathy) who have either symptomatic or asymptomatic must have evidence of cardiac involvement by echocardiogram as defined by left ventricle wall thickness of ≥ 12 mm and with at least one of the following criteria:; Positive scintigraphy by 99mTC-DPD [99mTC-3,3-diphosphono-1,2-propano-dicarboxylic acid] or 99mTC-PYP [Pyrophosphate] or 99mTC-HMDP [hydroxymethylene diphosphate] with Perugini grade ≥ 2 and/or H/CL (heart to contralateral lung) ratio > 1.5; Positive scintigraphy by 99mTC-DPD [99mTC-3,3-diphosphono-1,2-propano-dicarboxylic acid] or 99mTC-PYP [Pyrophosphate] or 99mTC-HMDP [hydroxymethylene diphosphate] with Perugini grade 1 and positive cardiac biopsy tissue confirmed which Congo red stain ≥ 4 sites; Positive scintigraphy by 99mTC-DPD [99mTC-3,3-diphosphono-1,2-propano-dicarboxylic acid] or 99mTC-PYP [Pyrophosphate] or 99mTC-HMDP [hydroxymethylene diphosphate] with Perugini grade 1 with positive non-cardiac biopsy tissue confirmed by Congo red stain; Abnormalities on CMR (Cardiac MRI) [Subendocardium LGE (late gadolinium enhancement) and/or elevated native T1 value and/or increased extracellular volume (ECV > 0.4)] with positive non-cardiac and/or cardiac tissue biopsy confirmed by Congo red stain.
Exclusion: Diagnosed with amyloidosis caused by proteins other than transthyretin (light chain Amyloidosis, etc.); Diagnosed with secondary amyloidosis.